Zapata Quantum (OTC: ZPTA) completed a $15 million financing round led by Triatomic Capital, marking the end of a year-long restructuring process. The quantum computing software company said the round was oversubscribed and included participation from other strategic investors.

The Boston-based company, which emerged from Harvard's Quantum Computing Lab in 2017, develops quantum computing applications and algorithms for enterprise clients. Zapata holds more than 60 granted and pending patents in quantum software technology.

"We've completed our restructuring and emerged stronger than ever," said Sumit Kapur, Chief Executive Officer of Zapata Quantum. "This financing is a strong vote of confidence from long-term, fundamentals-oriented investors and positions us to scale at a critical moment as quantum computing transitions from technical progress to transformational real-world value creation."

The company plans to use the funding to expand its platform and team across science, engineering, product, and commercial functions. Zapata operates as a hardware-agnostic quantum software platform, working with Fortune 500 enterprises and government agencies in sectors including cryptography, pharmaceuticals, finance, materials discovery, and defense.

Recent work by Zapata in quantum-enabled drug discovery was selected as one of Nature Biotechnology's top 10 scientific papers of 2025. The study, conducted with Dana-Farber Cancer Institute, University of Toronto, and Insilico Medicine, focused on targeting the KRAS mutation in cancer therapy.

Jeff Huber, General Partner of Triatomic Capital, said the firm was supporting Zapata's growth as it demonstrates leadership in translating quantum advantage into practical applications.

The company has participated in all technical areas of DARPA's Quantum Benchmarking program and maintains a collaboration with the University of Maryland on formal validation of quantum algorithms.